AngioDynamics price target raised to $16 from $13 at Oppenheimer

Oppenheimer raised the firm’s price target on AngioDynamics (ANGO) to $16 from $13 and keeps an Outperform rating on the shares. AngioDynamics’ Q2 sales exceeded the Street’s estimates, with MedTech sales the upside driver, with particular strength in mechanical thrombectomy, the analyst tells investors in a research note. NanoKnife is also positioned for acceleration with prostate approval on hand, the firm says.